A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

Phase 2

Terminated

Interventions: Diagnostic Test: collection of serum/capillary creatinine values

Brief Summary: This study is intended to investigate the usefulness of estimated glomerular filtration rate (eGFR) slopes derived from retrospective routine clinical practice data, compare those retrospective slopes with those generated in a prospective fashion and successively identify rapidly progressing chronic kidney disease (CKD) patients.

Recruitment & Eligibility

Inclusion Criteria

Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Manufacturing Practice (ICH-GCP) and local legislation prior to admission to the trial.
Patients with available medical records for data abstraction to meet the objectives of the study.
Male or female patients aged ≥ 18 years at time of consent.
Body Mass Index (BMI) ≥ 18.5 and < 50 kg/m² at Visit 1.
Clinical diagnosis of Chronic Kidney Disease (CKD).
Estimated Glomerular Filtration Rate (eGFR) decline of at least 1ml/min/1.73m²/year based on historical data from (electronic) medical records.
eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) 20 - 90 ml/min/1.73m² at Visit 1 calculated from serum creatinine measured by a central laboratory.
Patients are expected to be on optimal and stable background treatment (according to local therapy guidelines).
At least 4 serum creatinine values in the retrospective phase:
- The most recent creatinine value not more than 6 months prior to Visit 1 (Screening Visit).
- The most recent and oldest serum creatinine values should be no less than 1 year apart and no greater than 5 years apart.
- There should be no gap of creatinine values of 2 years or longer.

Exclusion Criteria

Changes in CKD or other key background treatments (including dose changes) known to impact eGFR values, over the past 4 weeks for Angiotensin Converting Enzyme inhibitors (ACEis) and Angiotensin Receptor Blockers (ARBs) and 8 weeks for Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors prior to Screening.
Autosomal Dominant Polycystic Kidney Disease (ADPKD), uncontrolled lupus nephritis, in the opinion of investigators.
Any iv immune suppression therapy within the last 3 months prior to Visit 1 or anyone currently on >45 mg prednisolone (or equivalent).
Acute kidney injury (AKI) according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition in the 30 days prior to Visit 1 until the start of trial assessments.
Planned start of chronic renal replacement therapy during the trial or end stage renal disease (i.e < 15 ml/min at 2 measurements 30 days apart) before start of trial assessments.
Medical history of cancer or treatment for cancer in the last two years prior to Visit 1 (except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix, and prostatic cancer of low grade [T1 or T2]).
Major surgery (investigator's judgement) planned during the trial.
Currently enrolled in an investigational device or drug trial, i.e., less than 30 days before Visit 1 since ending an investigational device or drug trial(s) or receiving investigational treatment(s).

Further exclusion criteria apply.

Arm && Interventions

Group	Intervention	Description
Patients with chronic kidney disease - overall population	collection of serum/capillary creatinine values	Patients with chronic kidney disease (CKD), including patients with non-diabetic chronic kidney disease (non-DKD) and diabetic kidney disease (DKD). Participants in this study did not receive any medication or study drug.

Primary Outcome Measures

Name	Time	Method
Homogeneity (eGFR Slope Shift Table) Between eGFR Slopes Derived From Retrospective and Prospective eGFR Values	Prospective slopes: All measurements from baseline until the last available visit were considered for inclusion in the estimation, including unscheduled visits, up to 48 weeks. Retrospective slopes: up to 66 months.	Retrospective and prospective slopes were derived using a linear random slope model. The prospective estimated Glomerular Filtration Rate (eGFR) slope for each patient was derived using eGFR values in the prospective phase as the dependent variable and time in the prospective phase as the continuous independent variable with random intercept and random slope. The retrospective eGFR slope for each patient was derived similarly using the data in the retrospective phase, and the time in the retrospective phase calculated relative to the first retrospective measurement per patient. Homogeneity was primarily evaluated via a shift analysis with categories of eGFR decline rate of 1 to \< 3 (slow) and \>= 3 ml/min/1.73m2/year (fast), in each of the retrospective and prospective phases. eGFR data collected 4 weeks before acute kidney injury and up to 8 weeks after acute kidney injury, and eGFR data occurring after changes to baseline background therapy (SGLT2i/ACEi/ARB) were excluded.

Secondary Outcome Measures

Name	Time	Method

Locations (19): Med-Care Research
🇺🇸
Miami, Florida, United States
International Research Associates
🇺🇸
Miami, Florida, United States
Tidewater Kidney Specialists
🇺🇸
Chesapeake, Virginia, United States
Szent Imre Korhaz, Budapest
🇭🇺
Budapest, Hungary
DRC Drug Research Ltd
🇭🇺
Balatonfured, Hungary
Nephrology Consultants, LLC
🇺🇸
Huntsville, Alabama, United States
Kidney & Hypertension Center
🇺🇸
Victorville, California, United States
Desert Cities Dialysis - Amethyst
🇺🇸
Victorville, California, United States
Davita Clinical Research-Hartford
🇺🇸
Bloomfield, Connecticut, United States
Nephrology & Hypertension Assoc., PC
🇺🇸
Middlebury, Connecticut, United States
Columbus Regional Research Institute
🇺🇸
Columbus, Georgia, United States
Kidney Medical Associates, PLLC
🇺🇸
Bronx, New York, United States
Sunbeam Clinical Research
🇺🇸
Greenville, Texas, United States
DaVita Clinical Research (DCR) Spartanburg
🇺🇸
Spartanburg, South Carolina, United States
DaVita Clinical Research Germany GmbH
🇩🇪
Geilenkirchen, Germany
InnoDiab Forschung GmbH
🇩🇪
Essen, Germany
Hospital Virgen Macarena
🇪🇸
Sevilla, Spain
DaVita Clinical Research
🇺🇸
Wauwatosa, Wisconsin, United States
Davita Clinical Research
🇺🇸
El Paso, Texas, United States